Canada markets close in 29 minutes

Inovio Pharmaceuticals, Inc. (INO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.46-0.49 (-4.47%)
As of 3:30PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close10.95
Open10.67
Bid10.45 x 1300
Ask10.46 x 800
Day's Range10.35 - 10.93
52 Week Range2.09 - 33.79
Volume3,670,316
Avg. Volume18,822,846
Market Cap1.752B
Beta (5Y Monthly)1.02
PE Ratio (TTM)N/A
EPS (TTM)-1.85
Earnings DateAug. 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.71
  • 2 Coronavirus Stocks to Avoid This Month
    Motley Fool

    2 Coronavirus Stocks to Avoid This Month

    Inovio Pharmaceuticals (NASDAQ: INO) and Gilead Sciences (NASDAQ: GILD) are major competitors in the growing market for coronavirus products, making both tantalizing stock picks. Inovio's stock has soared this year thanks to its INO-4800 coronavirus vaccine project, which has so far proven effective at producing immunity in primates. In contrast, Gilead's stock has consistently struggled despite the commercialization of its antiviral drug, remdesivir, which may be effective at helping patients recover from COVID-19.

  • Better Coronavirus Stock: Inovio Pharmaceuticals or VBI Vaccines?
    Motley Fool

    Better Coronavirus Stock: Inovio Pharmaceuticals or VBI Vaccines?

    Two biotech stocks that certainly fall into that group are Inovio Pharmaceuticals (NASDAQ: INO) and VBI Vaccines (NASDAQ: VBIV). Inovio's shares are up 259% year to date after rising as much as 860% at one point. VBI Vaccines stock is up 109% after jumping as high as 347% in July.

  • What You Need to Know at This Stage of the Coronavirus Vaccine Race
    Motley Fool

    What You Need to Know at This Stage of the Coronavirus Vaccine Race

    As of now, 10 programs are involved in phase 3 studies. The Vaccines and Related Biological Products Advisory Committee will meet Oct. 22 to discuss studies that should be performed to further confirm vaccine candidates' safety and efficacy (whether pre- or post-approval). In a briefing document, the FDA emphasized that any emergency use authorization (EUA) must be supported by phase 3 data.